PMID- 35979441
OWN - NLM
STAT- MEDLINE
DCOM- 20220819
LR  - 20220826
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Association between Chinese visceral adiposity index and metabolic-associated 
      fatty liver disease in Chinese adults with type 2 diabetes mellitus.
PG  - 935980
LID - 10.3389/fendo.2022.935980 [doi]
LID - 935980
AB  - OBJECTIVE: The purpose of the study was to determine the correlation of the 
      Chinese visceral adiposity index (CVAI) with metabolic-associated fatty liver 
      disease (MAFLD) in Chinese adults with type 2 diabetes mellitus (T2DM). 
      MATERIALS/METHODS: In this cross-sectional study, data on sociodemographic 
      characteristics, laboratory test results, coexisting diseases, and medical 
      therapy were collected and analyzed. Multivariate logistic regression analyses 
      were used to examine the correlation between CVAI and MAFLD. In order to 
      investigate the correlation between CVAI on a continuous scale and MAFLD, a 
      restricted cubic spline (RCS) was used. RESULTS: A total of 679 participants were 
      included in this study. There were 251 female participants and 428 male 
      participants, with a median age of 55 years. In the multivariate logistic 
      regression model, diastolic blood pressure, duration of diabetes, glycated 
      hemoglobin, hemoglobin, alanine transaminase, aspartate aminotransferase, gamma 
      -glutamyl transferase, albumin, blood urea nitrogen, total cholesterol, 
      low-density lipoprotein cholesterol, statin use and metformin use were adjusted, 
      and an evident increase in the odds ratios of MAFLD from the lowest to the 
      highest CVAI quartile was found (P value for trend < 0.001). Moreover, the RCS 
      curves revealed a positive correlation between CVAI and MAFLD. CONCLUSIONS: The 
      CVAI is positively correlated with MAFLD and may be an indicator with diagnostic 
      value for MAFLD in clinical practice in type 2 diabetic patients.
CI  - Copyright (c) 2022 Tang, Wei, Cao, Zhen, Liu, Wang, Fan and Peng.
FAU - Tang, Min
AU  - Tang M
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wei, Xiao-Hui
AU  - Wei XH
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Cao, Han
AU  - Cao H
AD  - Shanghai General Hospital of Nanjing Medical University, Shanghai, China.
AD  - Department of Endocrinology, Songjiang District Central Hospital, Shanghai, 
      China.
FAU - Zhen, Qin
AU  - Zhen Q
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Liu, Fang
AU  - Liu F
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Yu-Fan
AU  - Wang YF
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Fan, Neng-Guang
AU  - Fan NG
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
FAU - Peng, Yong-De
AU  - Peng YD
AD  - Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai 
      Jiao Tong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220801
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Cholesterol, LDL)
SB  - IM
MH  - Adiposity
MH  - Adult
MH  - China/epidemiology
MH  - Cholesterol, LDL
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Female
MH  - Humans
MH  - *Liver Diseases
MH  - Male
MH  - Middle Aged
MH  - Obesity, Abdominal/complications
PMC - PMC9376620
OTO - NOTNLM
OT  - Chinese visceral adiposity index
OT  - metabolic-associated fatty liver disease
OT  - non-alcoholic fatty liver disease
OT  - type 2 diabetes mellitus
OT  - visceral adiposity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/19 06:00
MHDA- 2022/08/20 06:00
PMCR- 2022/01/01
CRDT- 2022/08/18 02:19
PHST- 2022/05/04 00:00 [received]
PHST- 2022/07/11 00:00 [accepted]
PHST- 2022/08/18 02:19 [entrez]
PHST- 2022/08/19 06:00 [pubmed]
PHST- 2022/08/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.935980 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Aug 1;13:935980. doi: 
      10.3389/fendo.2022.935980. eCollection 2022.